Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms

Laboratory Investigation

Volumn 74, Issue 6, 1996, Pages 1105-1115

  Abu Jawdeh, Graziella M ^a   Faix, James D ^a   Niloff, Jonathan ^a   Tognazzi, Kathy ^a   Manseau, Eleanor ^a   Dvorak, Harold F ^a   Brown, Lawrence F ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR RECEPTOR; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN DETERMINATION; VASCULAR ENDOTHELIUM;

ADENOCARCINOMA; CAPILLARY PERMEABILITY; ENDOTHELIAL GROWTH FACTORS; FEMALE; FLUOROIMMUNOASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0029929046     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Augustin HG, Braun K, Telemanakis I, Modlich U, and Kuhn W (1995). Ovarian angiogenesis: Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am J Pathol 147:339-351.
2. Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, Clarke-Pearson DL, and Bast RCJ (1992). Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol 166:676-684.
3. Berse B, Brown LF, Van De Water L, Dvorak HF, and Senger DR (1992). Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211-220.
4. Boocock CA, Charnock-Jones S, Sharkey AM, McLaren J, Baker PJ, Wright KA, Twentyman PR, and Smith SK (1995). Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87:506-516.
5. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, and Schnitt SJ (1995). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91.
6. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, and Dvorak HF (1993a). Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143:1255-1262.
7. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau E, Senger R, and Dvorak HF (1993b). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53:4727-4735.
8. Brown LF, Berse B, Tognazzi K, Manseau EJ, VanDe Water L, R SD, Dvorak HF, and Rosen S (1992a). Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 42:1457-1461.
9. Brown LF, Yeo K-T, Berse B, Yeo T-K, Senger DR, Dvorak HF, and Van De Water L (1992b). Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176:1375-1379.
10. Claffey KP, Brown LF, Del Aguila LF, Tognazzi K, Yeo KT, J ME, and Dvorak HF (1996). Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56:172-181.
11. Conn G, Bayne ML, Soderman DD, Kwok PW, Sullivan KA, Palisi TM, Hope DA, and Thomas KA (1990). Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA 87:2628-2632.
12. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, R SN, Leimgruber RM, and Feder J (1989). Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470-1478.
13. Crickard K, Gross JL, Crickard U, Yoonesi M, Lele S, Herblin WF, and Eidsvoog K (1994). Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol 55:277-284.
14. Detmar M, Brown L, Claffey K, Yeo KT, Kocher O, RJ, Berse B, and Dvorak H (1994). Overexpression of vascular permeability factor (VPF/VEGF) and its receptors in psoriasis. J Exp Med 180:1141-1146.
15. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, and Williams LT (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991.
16. Di Blasio AM, Cremonesi L, Vigano P, Ferrari M, Gospodarowicz D, Vignali M, and Jaffe RB (1993). Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. Am J Obstet Gynecol 169:1517-1523.
17. Dolecki GJ and Connolly DT (1991). Effects of a variety of cytokines and inducing agents on vascular permeability factor mRNA levels in U937 cells. Biochem Biophys Res Commun 180:572-578.
18. Dvorak HF, Brown LF, Detmar M, and Dvorak AM (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039.
19. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, and Dvorak AM (1987). Fibrin-containing gels induce angiogenesis. Lab Invest 57:673-686.
20. Dvorak HF, Orenstein NS, Carvalho AC, Churchill WH, Dvorak AM, Galli SJ, Feder J, Bitzer AM, Rypysc J, and Giovinco P (1979). Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 122:166-174.
21. Dvorak HF, Sioussat TM, Brown LF, Nagy JA, Sotrel A, and Manseau E (1991). Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 174:1275-1278.
22. Fava R, Olsen N, G S-G, Yeo KT, Yeo TK, Berse B, Jackman R, Senger D, Dvorak H, and Brown L (1994). Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341-346.
23. Ferrara N and Henzel WJ (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851-858.
24. Fidler IJ and Ellis LM (1994). The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188.
25. Folkman J (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6.
26. Folkman J, Watson K, Ingber D, and Hanahan D (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61.
27. Gasparini G and Harris AL (1995). Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13:765-782.
28. Gospodarowicz D, Abraham JA, and Schilling J (1989). Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived follicular stellate cells. Proc Natl Acad Sci USA 86:7311-7315.
29. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, and Brown LF (1995). Angiogenesis and vascular permeability factor (vascular endothelial growth factor) expression in cervical neoplasia. J Natl Cancer Inst 87:1237-1245.
30. Henrickson R, Funa K, Wilander E, Backstrom T, Ridderheim M, and Oberg K (1993). Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53:4550-4554.
31. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, and Merino MJ (1995). Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147:33-41.
32. Jensenius JC, Andersen I, Hau J, Crone M, and Koch C (1981). Eggs: Conveniently packaged antibodies - Methods for purification of yolk IgG. J Immunol Methods 46:63-68.
33. Kamat BR, Brown LF, Manseau EJ, Senger DR, and Dvorak HF (1995). Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Am J Pathol 146:157-165.
34. Karlan BY and Platt LD (1995). Ovarian cancer screening: The role of ultrasound in early detection. Cancer 76:2011-2015.
35. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, and Connolly DT (1989). Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309.
36. Kim KJ, Li B, and Winer J (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844.
37. Koch A, Harlow L, Haines G, Amento E, Unemori E, Wong W, Rope R, and Ferrara N (1994). Vascular endothelial growth factor: A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152:4149-4156.
38. Kurachi H, Morishige K, Amemiya K, Adachi H, Hirota K, Miyake A, and Tanizawa O (1991). Importance of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vivo. Cancer Res 51:5956-5959.
39. Leake JF, Currie JL, Rosenshein NB, and Woodruff JD (1992). Long-term follow-up of serous ovarian tumor of low malignant potential. Gynecol Oncol 47:150-158.
40. Leung DW, Cachianes G, Kuang W, Goeddel DV, and Ferrara N (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309.
41. Liotta L, Kleinerman J, and Saidel G (1974). Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34:997-1004.
42. Mackey SE and Creasman WT (1995). Ovarian cancer screening. J Clin Oncol 13:783-793.
43. Millauer B, Shawver LK, Plate KH, Risau W, and Ullrich A (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576-579.
44. Olson TA, Mohanraj D, Carson LF, and Ramakrishnan S (1994). Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54:276-280.
45. Pepper MS, Ferrara N, Orci L, and Montesano R (1991). Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181:902-906.
46. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, and Alitalo K (1994). Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 269: 6271-6274.
47. Plate KH, Breier G, Weich HA, and Risau W (1992). Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359:845-848.
48. Reynolds K, Farzaneh F, Collins WP, Campbell S, Bourne TH, Lawton F, Moghaddam A, Harris AL, and Bicknell R (1994). Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 86:1234-1238.
49. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, and Dvorak HF (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
50. Senger DR, Perruzzi CA, Feder J, and Dvorak HF (1986). A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629-5632.
51. Shweiki D, Itin A, Soffer D, and Keshet E (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845.
52. Stromberg K, Collins TJT, Gordin AW, Jackson CL, Johnson GR, and Collins TJ (1992). Transforming growth factor-alpha acts as an autocrine growth factor in ovarian carcinoma cell lines. Cancer Res 52:341-347.
53. Stromberg K, Johnson GR, O'Connor DM, Sorensen CM, Gullick WJ, and Kannan B (1994). Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis. Int J Gynecol Pathol 13:342-347.
54. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, and Shows TB (1991). Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6:1677-1683.
55. Van Diest PJ, Zevering JP, Zevering LC, and Baak PA (1995). Prognostic value of microvessel quantitation in cisplatin treated FIGO 3 and 4 ovarian cancer patients. Pathol Res Pract 191:25-30.
56. van Nagell JR Jr, Gallion HH, Pavlik EJ, DePriest PD (1995). Ovarian cancer screening. Cancer 76:2086-2091.
57. Weidner N, Semple JP, Welch WR, and Folkman J (1991). Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 324:1-8.
58. Wu CC, Lee CN, Chen TM, Shyu MK, Hsieh CY, Chen HY, and Hsieh FJ (1994). Incremental angiogenesis assessed by color Doppler ultrasound in the tumorigenesis of ovarian neoplasms. Cancer 73:1251-1256.
59. Yeo KT, Sioussat TM, Faix JD, Senger DR, and Yeo TK (1992). Development of time-resolved immunofluorometric assay of vascular permeability factor. Clin Chem 38:71-75.
60. Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF, and Yeo TK (1993). Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 53:2912-2918.